Robert W. Robey

17.4k total citations · 2 hit papers
159 papers, 13.8k citations indexed

About

Robert W. Robey is a scholar working on Oncology, Molecular Biology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, Robert W. Robey has authored 159 papers receiving a total of 13.8k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Oncology, 90 papers in Molecular Biology and 29 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in Robert W. Robey's work include Drug Transport and Resistance Mechanisms (93 papers), Cancer therapeutics and mechanisms (31 papers) and Pharmacological Effects and Toxicity Studies (26 papers). Robert W. Robey is often cited by papers focused on Drug Transport and Resistance Mechanisms (93 papers), Cancer therapeutics and mechanisms (31 papers) and Pharmacological Effects and Toxicity Studies (26 papers). Robert W. Robey collaborates with scholars based in United States, China and Hungary. Robert W. Robey's co-authors include Susan E. Bates, Tito Fojo, Orsolya Polgár, Michael M. Gottesman, Antonio Tito Fojo, Thomas Litman, Matthew D. Hall, Suresh V. Ambudkar, Kristen M. Pluchino and Michael Dean and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Robert W. Robey

156 papers receiving 13.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Revisiting the role of ABC transporters in multidrug-resistant cancer

2018 1.4k citations Robert W. Robey, Kristen M. Pluchino et al. Nature reviews. Cancer profile →
Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes.

1999 674 citations Thomas Litman, Zhirong Zhan et al. profile →

Peers

Countries citing papers authored by Robert W. Robey

Since Specialization

Citations

This map shows the geographic impact of Robert W. Robey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert W. Robey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert W. Robey more than expected).

Fields of papers citing papers by Robert W. Robey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert W. Robey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert W. Robey. The network helps show where Robert W. Robey may publish in the future.

Co-authorship network of co-authors of Robert W. Robey

This figure shows the co-authorship network connecting the top 25 collaborators of Robert W. Robey. A scholar is included among the top collaborators of Robert W. Robey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert W. Robey. Robert W. Robey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Progress in characterizing ABC multidrug transporters in zebrafish 2023 ·Drug Resistance Updates ·(unknown), (unknown), Robert W. Robey, Michael M. Gottesman	5
2	Novel Therapeutic Strategies Exploiting the Unique Properties of Neuroendocrine Neoplasms 2023 ·Cancers ·(unknown), Luigi Scotto, Thomas Litman, (unknown), Hu Zhu, Min Shen, Robert W. Robey, Matthew D. Hall, Tito Fojo, Susan E. Bates	1
3	R-Loop–Mediated ssDNA Breaks Accumulate Following Short-Term Exposure to the HDAC Inhibitor Romidepsin 2021 ·Molecular Cancer Research ·(unknown), Thomas Litman, Robert W. Robey, Andrés Aguilera, Arup R. Chakraborty, William C. Reinhold, Agnès Basseville, (unknown), Luigi Scotto, Owen A. O’Connor, Yves Pommier, Antonio Tito Fojo, Susan E. Bates	19
4	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein 2019 ·Molecular Pharmacology ·Tobie D. Lee, Olivia W. Lee, Kyle R. Brimacombe, Lu Chen, Rajarshi Guha, Sabrina Lusvarghi, (unknown), Carleen Klumpp‐Thomas, Robert W. Robey, Suresh V. Ambudkar, Min Shen, Michael M. Gottesman, Matthew D. Hall	22
5	Mycoplasma Infection Mediates Sensitivity of Multidrug-Resistant Cell Lines to Tiopronin: A Cautionary Tale 2019 ·Journal of Medicinal Chemistry ·Lyn M. Huff, Sachi Horibata, Robert W. Robey, Matthew D. Hall, Michael M. Gottesman	5
6	Revisiting the role of ABC transporters in multidrug-resistant cancer breakdown → 2018 ·Nature reviews. Cancer ·Robert W. Robey, Kristen M. Pluchino, Matthew D. Hall, Antonio Tito Fojo, Susan E. Bates, Michael M. Gottesman	1382
7	Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins 2015 ·Proceedings of the National Academy of Sciences ·Marianne S. Poruchynsky, Edina Komlódi-Pásztor, Shana Y. Trostel, Julia Wilkerson, Marie Regairaz, Yves Pommier, Xu Zhang, Tapan K. Maity, Robert W. Robey, Mauricio Burotto, Dan L. Sackett, Udayan Guha, Antonio Tito Fojo	150
8	Mithramycin Represses Basal and Cigarette Smoke–Induced Expression of ABCG2 and Inhibits Stem Cell Signaling in Lung and Esophageal Cancer Cells 2012 ·Cancer Research ·Mary Zhang, Aarti Mathur, Yuwei Zhang, Sichuan Xi, Scott M. Atay, Julie A. Hong, (unknown), Trevor Upham, Clinton D. Kemp, R. Taylor Ripley, Gordon Wiegand, (unknown), Patricia Fetsch, Haresh Mani, Daniel Zlott, Robert W. Robey, Susan E. Bates, Xinmin Li, Mahadev Rao, David S. Schrump	82
9	Histone Deacetylase Inhibitors Influence Chemotherapy Transport by Modulating Expression and Trafficking of a Common Polymorphic Variant of the ABCG2 Efflux Transporter 2012 ·Cancer Research ·Agnès Basseville, Akina Tamaki, Caterina Ieranò, Shana Y. Trostel, Yvona Ward, Robert W. Robey, Ramanujan S. Hegde, Susan E. Bates	32
10	Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway 2011 ·Molecular Cancer Research ·Kenneth K.W. To, Robert W. Robey, Zhirong Zhan, (unknown), Susan E. Bates	43
11	Sildenafil Reverses ABCB1- and ABCG2-Mediated Chemotherapeutic Drug Resistance 2011 ·Cancer Research ·Zhi Shi, Amit K. Tiwari, Suneet Shukla, Robert W. Robey, Satyakam Singh, In‐Wha Kim, Susan E. Bates, Xingxiang Peng, Ioana Abraham, Suresh V. Ambudkar, Tanaji T. Talele, Liwu Fu, Zhe‐Sheng Chen	152
12	A Pharmacodynamic Study of Docetaxel in Combination with the P-glycoprotein Antagonist Tariquidar (XR9576) in Patients with Lung, Ovarian, and Cervical Cancer 2010 ·Clinical Cancer Research ·Ronan J. Kelly, Deborah Draper, Clara C. Chen, Robert W. Robey, William D. Figg, Richard Piekarz, Xiaohong Chen, Erin R. Gardner, Frank M. Balis, Aradhana M. Venkatesan, Seth M. Steinberg, Tito Fojo, Susan E. Bates	151
13	A Phase I Study of the P-Glycoprotein Antagonist Tariquidar in Combination with Vinorelbine 2009 ·Clinical Cancer Research ·Jame Abraham, Maureen Edgerly, Richard H. Wilson, Clara Chen, Ann Rutt, Susan Bakke, Robert W. Robey, (unknown), Barry R. Goldspiel, Frank M. Balis, Olaf van Tellingen, Susan E. Bates, Tito Fojo	93
14	Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2 2009 ·Molecular Cancer Therapeutics ·Kenneth K.W. To, Robert W. Robey, Turid Knutsen, Zhirong Zhan, Thomas Ried, Susan E. Bates	86
15	Lapatinib (Tykerb, GW572016) Reverses Multidrug Resistance in Cancer Cells by Inhibiting the Activity of ATP-Binding Cassette Subfamily B Member 1 and G Member 2 2008 ·Cancer Research ·Chun-ling Dai, Amit K. Tiwari, Chung‐Pu Wu, Xiao‐Dong Su, (unknown), (unknown), Charles R. Ashby, Yan Huang, Robert W. Robey, Yong‐ju Liang, Liming Chen, (unknown), Suresh V. Ambudkar, Zhe‐Sheng Chen, Liwu Fu	333
16	Evidence for Microtubule Target Engagement in Tumors of Patients Receiving Ixabepilone 2007 ·Clinical Cancer Research ·Sen Hong Zhuang, (unknown), (unknown), Robert W. Robey, Dan L. Sackett, W. Marston Linehan, Susan E. Bates, Tito Fojo, Marianne S. Poruchynsky	23
17	ABCG2 expression, function and a SNP variant in the NCI drug screen cell lines 2006 ·Cancer Research ·John F. Deeken, Robert W. Robey, Zhirong Zhan, Susan E. Bates	1
18	The Q141K single-nucleotide polymorphism impacts the transporter activity of ABCG2. 2004 ·Cancer Research ·Kuniaki Morisaki, Robert W. Robey, (unknown), Csilla Özvegy, Yasumasa Honjo, Lyn M. Huff, Alex Sparreboom, Balázs Sarkadi, Susan E. Bates	4
19	A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma 2002 ·Cancer ·Jame Abraham, Susan Bakke, Ann Rutt, Beverly Meadows, Maria Merino, Richard H. Alexander, David S. Schrump, David B. Bartlett, Peter Choyke, Robert W. Robey, (unknown), Seth M. Steinberg, Susan E. Bates, Tito Fojo	82
20	Reversal of Multidrug Resistance: Lessons from Clinical Oncology 2002 ·Novartis Foundation symposium ·Susan E. Bates, Clara Chen, Robert W. Robey, Min H. Kang, William D. Figg, Tito Fojo	59

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact